Structural highlights
Publication Abstract from PubMed
A novel imidazo-pyramidazine inhibitor of DAPK1 that undergoes class-specific interactions and extends into the substrate recognition site has been identified. This inhibitor is a good starting point for the development of selective and potent inhibitors of DAPK1, with potential use against stroke and ischemia.
Identification and Characterization of a Small-Molecule Inhibitor of Death-Associated Protein Kinase 1.,Wilbek TS, Skovgaard T, Sorrell FJ, Knapp S, Berthelsen J, Stromgaard K Chembiochem. 2014 Nov 7. doi: 10.1002/cbic.201402512. PMID:25382253[1]
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
References
- ↑ Wilbek TS, Skovgaard T, Sorrell FJ, Knapp S, Berthelsen J, Stromgaard K. Identification and Characterization of a Small-Molecule Inhibitor of Death-Associated Protein Kinase 1. Chembiochem. 2014 Nov 7. doi: 10.1002/cbic.201402512. PMID:25382253 doi:http://dx.doi.org/10.1002/cbic.201402512
